Critical evaluation of causality assessment of herb–drug interactions in patients

British Journal of Clinical Pharmacology

Volumn 84, Issue 4, 2018, Pages 679-693

  Awortwe, Charles ^a,b   Makiwane, Memela ^b   Reuter, Helmuth ^b   Muller, Christo ^a   Louw, Johan ^a   Rosenkranz, Bernd ^b  

^a SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

adverse drug reactions; causality assessment; herb induced liver injury; herbal drugs; herb drug interactions; side effects

Indexed keywords

ALKYLATING AGENT; CYCLOSPORINE; WARFARIN; PLANT MEDICINAL PRODUCT;

ADVERSE DRUG REACTION; CARDIOVASCULAR DISEASE; CAUSALITY; DISEASE SEVERITY ASSESSMENT; HERB DRUG INTERACTION; HERBAL MEDICINE; HUMAN; KIDNEY GRAFT; MALIGNANT NEOPLASM; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HERB-DRUG INTERACTIONS; HUMANS; PLANT PREPARATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 85041128198     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.13490     Document Type: Review

References (114)

1. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol 2014; 4: 177.
2. NCD Risk Factor Collaboration (NCD-RisC) – Africa Working Group. Trends in obesity and diabetes across Africa from 1980 to 2014: an analysis of pooled population-based studies. Int J Epidemiol 2017; Available from: http://www.ncbi.nlm.nih.gov/pubmed/28582528.
3. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 2016; 387: 1513–1530.
4. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet 2017; 389: 37–55.
5. Benziger CP, Roth GA, Moran AE. The global burden of disease study and the preventable burden of NCD. Glob Heart 2016; 11: 393–397.
6. Duan W, Zheng A, Mu X, Li M, Liu C, Huang W, et al. How great is the medical burden of disease on the aged? Research based on “System of Health Account 2011”. Health Qual Life Outcomes 2017; 15: 134.
7. Weiss CO. Frailty and chronic diseases in older adults. Clin Geriatr Med 2011; 27: 39–52.
8. Saraga M, Zullino DF. St. John's Wort, corticosteroids, cocaine, alcohol.. and a first manic episode. Praxis (Bern 1994) 2005; 94: 987–989.
9. Moschella C, Jaber BL. Interaction between cyclosporine and Hypericum perforatum (St. John's wort) after organ transplantation. Am J Kidney Dis 2001; 38: 1105–1107.
10. Dannawi M. Possible serotonin syndrome after combination of buspirone and St John's Wort. J Psychopharmacol 2002; 16: 401.
11. Spinella M, Eaton LA. Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury. Brain Inj 2002; 16: 359–367.
12. Awortwe C, Fasinu PS, Rosenkranz B. Application of Caco-2 cell line in herb-drug interaction studies: current approaches and challenges. J Pharm Pharm Sci 2014; 17: 1–19.
13. Hong M, Li S, Tan HY, Cheung F, Wang N, Huang J, et al. A network-based pharmacology study of the herb-induced liver injury potential of traditional hepatoprotective Chinese herbal medicines. Molecules 2017; 22: 28420096.
14. Sun D, Zhang C-Z, Ran R-X, Cao Y-F, Du Z, Fu Z-W, et al. In vitro comparative study of the inhibitory effects of mangiferin and its aglycone norathyriol towards UDP-glucuronosyl transferase (UGT) isoforms. Molecules 2017; 22: 28621744.
15. Jackson JP, Freeman KM, Friley WW, Herman AG, Black CB, Brouwer KR, et al. Prediction of clinically relevant herb–drug clearance interactions using sandwich-cultured human hepatocytes: Schisandra spp. Case Study Drug Metab Dispos 2017; 45: 1019–1026.
16. Dai G, Jiang Z, Bai Y, Zhang Q, Zhu L, Bai X, et al. Pharmacokinetic herb–drug interaction of Xuesaitong dispersible tablet and aspirin after oral administration in blood stasis model rats. Phytomedicine 2017; 26: 62–68.
17. Ting CT, Cheng YY, Tsai TH. Herb–drug interaction between the traditional hepatoprotective formulation and sorafenib on hepatotoxicity, histopathology and pharmacokinetics in rats. Molecules 2017; 22: 28640225.
18. Thomford NE, Awortwe C, Dzobo K, Adu F, Chopera D, Wonkam A, et al. Inhibition of CYP2B6 by medicinal plant extracts: implication for use of efavirenz and nevirapine-based highly active anti-retroviral therapy (HAART) in resource-limited settings. Molecules 2016; 21: 26891286.
19. Patel O, Muller C, Joubert E, Louw J, Rosenkranz B, Awortwe C. Inhibitory interactions of Aspalathus linearis (rooibos) extracts and compounds, aspalathin and z-2-(β-d-glucopyranosyloxy)-3-phenylpropenoic acid, on cytochromes metabolizing hypoglycemic and hypolipidemic drugs. Molecules 2016; 21: 27845750.
20. Awortwe C, Manda VK, Avonto C, Khan SI, Khan IA, Walker LA, et al. Echinacea purpurea up-regulates CYP1A2, CYP3A4 and MDR1 gene expression by activation of pregnane X receptor pathway. Xenobiotica 2015; 45: 218–229.
21. Awortwe C, Manda VK, Avonto C, Khan SI, Khan IA, Walker LA, et al. In vitro evaluation of reversible and time-dependent inhibitory effects of Kalanchoe crenata on CYP2C19 and CYP3A4 activities. Drug Metab Lett 2015; 9: 48–62.
22. Awortwe C, Bouic PJ, Masimirembwa CM, Rosenkranz B. Inhibition of major drug metabolizing CYPs by common herbal medicines used by HIV/AIDS patients in Africa- implications for herb-drug interactions. Drug Metab Lett 2014; 7: 83–95.
23. Kim B-H, Kim K-P, Lim KS, Kim J-R, Yoon SH, Cho J-Y, et al. Influence of Ginkgo biloba extract on the pharmacodynamic effects and pharmacokinetic properties of ticlopidine: an open-label, randomized, two-period, two-treatment, two-sequence, single-dose crossover study in healthy Korean male volunteers. Clin Ther 2010; 32: 380–390.
24. Penzak SR, Robertson SM, Hunt JD, Chairez C, Malati CY, Alfaro RM, et al. Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects. Pharmacotherapy 2010; 30: 797–805.
25. Goey AKL, Meijerman I, Rosing H, Burgers JA, Mergui-Roelvink M, Keessen M, et al. The effect of Echinacea purpurea on the pharmacokinetics of docetaxel. Br J Clin Pharmacol 2013; 76: 467–474.
26. Monera-Penduka TG, Maponga CC, Wolfe AR, Wiesner L, Morse GD, Nhachi CFB. Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study. AIDS Res Ther 2017; 14: 12.
27. Gwaza L, Aweeka F, Greenblatt R, Lizak P, Huang L, Guglielmo BJ. Co-administration of a commonly used Zimbabwean herbal treatment (African potato) does not alter the pharmacokinetics of lopinavir/ritonavir. Int J Infect Dis 2013; 17: e857–e861.
28. Sprouse AA, van Breemen RB. Pharmacokinetic interactions between drugs and botanical dietary supplements. Drug Metab Dispos 2016; 44: 162–171.
29. Andrén L, Andreasson A, Eggertsen R. Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia. Eur J Clin Pharmacol 2007; 63: 913–916.
30. Zadoyan G, Rokitta D, Klement S, Dienel A, Hoerr R, Gramatté T, et al. Effect of Ginkgo biloba special extract EGb 761 on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers. Eur J Clin Pharmacol 2012; 68: 553–560.
31. Jeong TY, Park BK, Cho JH, Kim YI, Ahn YC, Son CG. A prospective study on the safety of herbal medicines, used alone or with conventional medicines. J Ethnopharmacol 2012; 143: 884–888.
32. Levy I, Attias S, Ben-Arye E, Goldstein L, Schiff E. Adverse events associated with interactions with dietary and herbal supplements among inpatients. Br J Clin Pharmacol 2017; 83: 836–845.
33. Rivera CA, Ferro CL, Bursua AJ, Gerber BS. Probable interaction between Lycium barbarum (goji) and warfarin. Pharmacotherapy 2012; 32: e50–e53.
34. Bilgi N, Bell K, Ananthakrishnan AN, Atallah E. Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. Ann Pharmacother 2010; 44: 926–928.
35. Seger D, Barker K, McNaughton C. Misuse of the Naranjo Adverse Drug Reaction Probability Scale in toxicology. Clin Toxicol (Phila) 2013; 51: 461–466.
36. Fugh-Berman A, Ernst E. Herb–drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 2001; 52: 587–595.
37. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007; 41: 674–680.
38. Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci 2015; 17 (1): 1–33.
39. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs – II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46: 1331–1336.
40. Danan G, Benichou C. Causality assessment of adverse reactions to drugs – I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323–1330.
41. Williamson E, Driver S, Baxter K. Stockly's herbal medicines interactions. London: Pharmaceutical press, 2009; 1–11.
42. Ji H, Zhang G, Yue F, Zhou X. Adverse event due to a likely interaction between sodium aescinate and Ginkgo biloba extract: a case report. J Clin Pharm Ther 2017; 42: 237–238.
43. Nayeri A, Wu S, Adams E, Tanner C, Meshman J, Saini I, et al. Acute calcineurin inhibitor nephrotoxicity secondary to turmeric intake: a case report. Transplant Proc 2017; 49: 198–200.
44. Damato A, Larocca M, Rondini E, Pinto C, Versari A, Menga M. Severe rhabdomylosis during treatment with trabectedin in combination with herbal drug in patient with metastatic synovial sarcoma: a case report. Case Rep Oncol 2017; 10: 258–264.
45. Khalid Z, Osuagwu FC, Shah B, Roy N, Dillon JE, Bradley R. Celery root extract as an inducer of mania induction in a patient on venlafaxine and St John's Wort. Postgrad Med 2016; 128: 682–683.
46. Kang YC, Chen MH, Lai SL. Potentially unsafe herb–drug interactions between a commercial product of noni juice and phenytoin – a case report. Acta Neurol Taiwan 2015; 24: 43–46.
47. Myers AP, Watson TA, Strock SB. Drug reaction with eosinophilia and systemic symptoms syndrome probably induced by a lamotrigine–ginseng drug interaction. Pharmacotherapy 2015; 35: e9–12.
48. Ferreira PG, Costa S, Dias N, Ferreira AJ, Franco F. Simultaneous interstitial pneumonitis and cardiomyopathy induced by venlafaxine. J Bras Pneumol 2014; 40: 313–318.
49. Melchardt T, Magnes T, Weiss L, Grundbichler M, Strasser M, Hufnagl C, et al. Liver toxicity during temozolomide chemotherapy caused by Chinese herbs. BMC Complement Altern Med 2014; 14: 115.
50. Carbajal R, Yisfalem A, Pradhan N, Baumstein D, Chaudhari A. Case report: Boldo (Peumus boldus) and tacrolimus interaction in a renal transplant patient. Transplant Proc 2014; 46: 2400–2402.
51. Carter J, Yeh RF, Braunschweig I, Barta SK. Unreported use of an herbal supplement resulting in decreased clearance of intravenous busulfan in a patient undergoing. Bone Marrow Transplant 2013; 49: 313–314.
52. Açikgöz SK, Açikgöz E. Gastrointestinal bleeding secondary to interaction of Artemisia absinthium with warfarin. Drug Metabol Drug Interact 2013; 28: 187–189.
53. Strippoli S, Lorusso V, Albano A, Guida M. Herbal-drug interaction induced rhabdomyolysis in a liposarcoma patient receiving trabectedin. BMC Complement Altern Med 2013; 13: 199.
54. Hou Q, Han W, Fu X. Pharmacokinetic interaction between tacrolimus and berberine in a child with idiopathic nephrotic syndrome. Eur J Clin Pharmacol 2013; 69: 1861–1862.
55. Orr A, Parker R. Red clover causing symptoms suggestive of methotrexate toxicity in a patient on high-dose methotrexate. Menopause Int 2013; 19: 133–134.
56. Tamura S, Warabi Y, Matsubara S. Severe liver dysfunction possibly caused by the combination of interferon beta-1b therapy and melilot (sweet clover) supplement. J Clin Pharm Ther 2012; 37: 724–725.
57. Van Strater ACP, Bogers JPAM. Interaction of St John's wort (Hypericum perforatum) with clozapine. Int Clin Psychopharmacol 2012; 27: 121–124.
58. Mateo-Carrasco H, Gálvez-Contreras MC, Fernández-Ginés FD, Nguyen TV. Elevated liver enzymes resulting from an interaction between raltegravir and Panax ginseng: a case report and brief review. Drug Metabol Drug Interact 2012; 27: 171–175.
59. Naccarato M, Yoong D, Gough K. A potential drug-herbal interaction between Ginkgo biloba and efavirenz. J Int Assoc Physicians AIDS Care 2012; 11: 98–100.
60. Bossaer JB, Odle BL. Probable etoposide interaction with Echinacea. J Diet Suppl 2012; 9: 90–95.
61. Uygur Bayramıçlı O, Kalkay MN, Oskay Bozkaya E, Doğan Köse E, Iyıgün O, Görük M, et al. St. John's wort (Hypericum perforatum) and warfarin: dangerous liaisons! Turk J Gastroenterol 2011; 22: 115.
62. Hamann GL, Campbell JD, George CM. Warfarin–cranberry juice interaction. Ann Pharmacother 2011; 45: e17.
63. Su Q, Li Y. Interaction between warfarin and the herbal product shengmai-yin: a case report of intracerebral hematoma. Yonsei Med J 2010; 51: 793–796.
64. Hurren KM, Lewis CL. Probable interaction between warfarin and bee pollen. Am J Health Syst Pharm 2010; 67: 2034–2037.
65. Sobieraj DM, Freyer CW. Probable hypoglycemic adverse drug reaction associated with prickly pear cactus, glipizide, and metformin in a patient with type 2 diabetes mellitus. Ann Pharmacother 2010; 44: 1334–1337.
66. Corrigan MA, Atkinson KM, Sha BE, Crank CW. Evaluation of pharmacy-implemented medication reconciliation directed at antiretroviral therapy in hospitalized HIV/AIDS patients. Ann Pharmacother 2010; 44: 222–223.
67. Gordon RY, Becker DJ, Rader DJ. Reduced efficacy of rosuvastatin by St. John's wort. Am J Med 2009; 122: e1–e2.
68. Prasad K, Tharangani PGD, Samaranayake CN. Recurrent relapses of depression in a patient established on sertraline after taking herbal medicinal mixtures – a herb–drug interaction? J Psychopharmacol 2009; 23: 216–219.
69. Carrasco MC, Vallejo JR, Pardo-de-Santayana M, Peral D, Martín MA, Altimiras J. Interactions of Valeriana officinalis L. and Passiflora incarnata L. in a patient treated with lorazepam. Phytother Res 2009; 23: 1795–1796.
70. Chang Y-Y, Liu J-S, Lai S-L, Wu H-S, Lan M-Y. Cerebellar hemorrhage provoked by combined use of nattokinase and aspirin in a patient with cerebral microbleeds. Intern Med 2008; 47: 467–469.
71. Beukel van den Bout-van den CJP, Bosch MEW, Burger DM, Koopmans PP, van der Ven AJAM. Toxic lopinavir concentrations in an HIV-1 infected patient taking herbal medications. AIDS 2008; 22: 1243–1244.
72. Hwang SW, Han HS, Lim KY, Han JY. Drug interaction between complementary herbal medicines and gefitinib. J Thorac Oncol 2008; 3: 942–943.
73. Werba JP, Giroli M, Cavalca V, Nava MC, Tremoli E, Dal BL. The effect of green tea on simvastatin tolerability. Ann Intern Med 2008; 149: 286–287.
74. Leung H, Hung A, Hui ACF, Chan TYK. Warfarin overdose due to the possible effects of Lycium barbarum L. Food Chem Toxicol 2008; 46: 1860–1862.
75. Iida R, Otsuka Y, Matsumoto K, Kuriyama S, Hosoya T. Pseudoaldosteronism due to the concurrent use of two herbal medicines containing glycyrrhizin: Interaction of glycyrrhizin with angiotensin-converting enzyme inhibitor. Clin Exp Nephrol 2006; 10: 131–135.
76. Segal R, Pilote L. Warfarin interaction with Matricaria chamomilla. CMAJ 2006; 174: 1281–1282.
77. Epstein RJ, Leung TWT, Cheung PSY. Panmucositis and chemosensitisation associated with betel quid chewing during dose-dense adjuvant breast cancer chemotherapy. Cancer Chemother Pharmacol 2006; 58: 835–837.
78. Al Faraj S. Antagonism of the anticoagulant effect of warfarin caused by the use of Commiphora molmol as a herbal medication: a case report. Ann Trop Med Parasitol 2017; 4983: 10–12.
79. Nowack R, Nowak B. Case report. Herbal teas interfere with cyclosporin levels in renal transplant patients. Nephrol Dial Transplant 2005; 20: 2554–2556.
80. Kupiec T, Raj V. Fatal seizures due to potential herb-drug interactions with Ginkgo biloba. J Anal Toxicol 2005; 29: 755–758.
81. Lee A, Chui PT, Aun CST, Gin T, Lau ASC. Possible interaction between sevoflurane and Aloe vera. Ann Pharmacother 2004; 38: 1651–1654.
82. Alscher DM, Klotz U. Drug interaction of herbal tea containing St. John's wort with cyclosporine. Transpl Int 2003; 16: 543–544.
83. Wong ALN, Chan TYK. Interaction between warfarin and the herbal product Quilinggao. Ann Pharmacother 2003; 37: 836–838.
84. Rasad GVRAP, Ong TIW, Eliton GALOM. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation 2001; 74: 1200–1201.
85. Lam AY, Elmer GW, Mohutsky MA. Possible interaction between warfarin and Lycium barbarum L. Ann Pharmacother 2001; 35: 1199–1201.
86. Lambert JP, Cormier J. Potential interaction between warfarin and boldo-fenugreek. Pharmacotherapy 2001; 21: 509–512.
87. Brown AC. Kidney toxicity related to herbs and dietary supplements: online table of case reports. Part 3 of 5 series. Food Chem Toxicol 2017; 107: 502–519.
88. Alsanad SM, Howard RL, Williamson EM. An assessment of the impact of herb–drug combinations used by cancer patients. BMC Complement Altern Med 2016; 16: 393.
89. Walji R, Boon H, Barnes J, Austin Z, Baker GR, Welsh S. Adverse event reporting for herbal medicines: a result of market forces. Healthc Policy 2009; 4: 77–90.
90. Skalli S, Bencheikh RS. Safety monitoring of herb–drug interactions. Drug Saf 2012; 35: 785–791.
91. Lee NJ, Pharm D, Fermo JD, Pharm D. Warfarin and royal jelly interaction. Pharmacotherapy 2006; 26: 583–586.
92. Nakajima S, Uchiyama Y, Yoshida K, Mizukawa H, Haruki E. The effects of ginseng radix rubra on human vascular endothelial cells. Am J Chin Med 1998; 26: 365–373.
93. Lü J, Ma Z, Yang J, Huang J, Wang S, Wang S. Ginsenoside Rg1-induced alterations in gene expression in TNF-alpha stimulated endothelial cells. Chin Med J (Engl) 2004; 117: 871–876.
94. Donovan JL, Chavin KD, Devane CL, Taylor RM, Wang JS, Ruan Y, et al. Green tea (Camellia sinensis) extract does not alter cytochrome P450 3A4 or 2D6 activity in healthy volunteers. Drug Metab Dispos 2004; 32: 906–908.
95. Chow H-HS, Hakim IA, Vining DR, Crowell JA, Cordova CA, Chew WM, et al. Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiol Biomarkers Prev 2006; 15: 2473–2476.
96. Egashira K, Sasaki H, Higuchi S, Ieiri I. Food-drug interaction of tacrolimus with pomelo, ginger, and turmeric juice in rats. Drug Metab Pharmacokinet 2012; 27: 242–247.
97. Zhang W, Tan TMC, Lim LY. Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats. Drug Metab Dispos 2007; 35: 110–115.
98. Zhang W, Lim LY. Effects of spice constituents on P-glycoprotein-mediated transport and CYP3A4-mediated metabolism in vitro. Drug Metab Dispos 2008; 36: 1283–1290.
99. Ganzera M, Schneider P, Stuppner H. Inhibitory effects of the essential oil of chamomile (Matricaria recutita L.) and its major constituents on human cytochrome P450 enzymes. Life Sci 2006; 78: 856–861.
100. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000; 7: 273–282.
101. Burdmann EA, Andoh TF, Yu L, Bennett WM. Cyclosporine nephrotoxicity. Semin Nephrol 2003; 23: 465–476.
102. Cuffari C. A physician's guide to azathioprine metabolite testing. Gastroenterol Hepatol (NY) 2006; 2: 58–63.
103. Ujhelyi MR, Bottorff MB, Schur M, Roll K, Zhang H, Stewart J, et al. Aging effects on the organic base transporter and stereoselective renal clearance. Clin Pharmacol Ther 1997; 62: 117–128.
104. Donovan JL, DeVane CL, Chavin KD, Taylor RM, Markowitz JS. Siberian ginseng (Eleutheroccus senticosus) effects on CYP2D6 and CYP3A4 activity in normal volunteers. Drug Metab Dispos 2003; 31: 519–522.
105. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, et al. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 2005; 22: 525–539.
106. Taki Y, Yamazaki Y, Shimura F, Yamada S, Umegaki K. Time-dependent induction of hepatic cytochrome P450 enzyme activity and mRNA expression by bilobalide in rats. J Pharmacol Sci 2009; 109: 459–462.
107. Deng Y, Bi H-C, Zhao L-Z, He F, Liu Y-Q, Yu J-J, et al. Induction of cytochrome P450s by terpene trilactones and flavonoids of the Ginkgo biloba extract EGb 761 in rats. Xenobiotica 2008; 38: 465–481.
108. Yin OQP, Tomlinson B, Waye MMY, Chow AHL, Chow MSS. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004; 14: 841–850.
109. Shannon M, McElroy EA, Liebelt EL. Toxic seizures in children: case scenarios and treatment strategies. Pediatr Emerg Care 2003; 19: 206–210.
110. Kuo YT, Chang TT, Muo CH, Wu MY, Sun MF, Yeh CC, et al. Use of complementary traditional Chinese medicines by adult cancer patients in Taiwan: a nationwide population-based study. Integr Cancer Ther 2017; 1; 1534735417716302.
111. Huet M. Medicinal plants in cancer patients: current practices and evaluation data. Bull Cancer 2013; 100: 485–495.
112. Poonthananiwatkul B, Howard RL, Williamson EM, Lim RHM. Cancer patients taking herbal medicines: a review of clinical purposes, associated factors, and perceptions of benefit or harm. J Ethnopharmacol 2015; 175: 58–66.
113. Akpunar D, Bebis H, Yavan T. Use of complementary and alternative medicine in patients with gynecologic cancer: a systematic review. Asian Pac J Cancer Prev 2015; 16: 7847–7852.
114. Bräunlich M, Christensen H, Johannesen S, Slimestad R, Wangensteen H, Malterud KE, et al. In vitro inhibition of cytochrome P450 3A4 by Aronia melanocarpa constituents. Planta Med 2013; 79: 137–141.